Cure8 research brief
This study compares bloodstream infection risk across commonly used biologics for IBD, which could affect decisions about choosing or monitoring biologic therapy. It also highlights that steroid co-use may increase infection risk.
Adults with IBD considering or receiving TNF inhibitors, vedolizumab, or ustekinumab; clinicians who prescribe or monitor biologics; researchers studying infection risks with immunomodulatory therapies.
This Danish nationwide case–control study (2010–2024) looked at microbiologically confirmed bloodstream infections (BSI) in people with IBD and compared current users of TNF inhibitors, vedolizumab, and ustekinumab to non-users.
The authors report that current use of TNF inhibitors was associated with higher overall BSI rates; vedolizumab and ustekinumab were not associated with increased overall BSI rates.
In pathogen-specific analyses, TNFi use was linked to higher rates of Escherichia coli and Staphylococcus aureus BSI, and vedolizumab was linked to higher rates of Enterococcus faecium BSI. The study used nationwide registries and matched each case to five IBD controls, defining current biologic use as recorded use within 180 days prior to the index date.
Concomitant systemic glucocorticoid use was associated with higher BSI rates among TNFi and vedolizumab users compared with biologic monotherapy. This brief summarizes the article abstract and its reported associations.
It does not replace clinical guidance; individual risk depends on factors not fully described in the abstract (disease activity, comorbidities, dosing, prior infections). If you take or prescribe these drugs, discuss infection risk and preventive measures with your care team.
Structured-content depth: abstract. The summary is grounded in the article abstract from Alimentary Pharmacology & Therapeutics. Registry-based observational studies can show associations but not definitive causation; unmeasured confounding (disease severity, prior infections, healthcare exposure) may influence results.
The abstract defines current biologic use as within 180 days of the index date and reports adjusted incidence rate ratios.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...
